Show results for
Refine by
Tumor Marker Articles & Analysis
23 news found
The scientists will collect blood from the patients and will measure the number and kind of tumor cells (cellular residual disease) and DNA (molecular residual disease) released from the tumor in the blood. ...
(“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle. ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
Additionally, the Company will be launching Point2Glucose™—a new pancreatic cyst fluid tumor marker diagnostic test offering that requires a very low volume of cyst fluid (0.2ml). ...
Cytokines play an important role in physiological and pathological processes such as immune cell differentiation and subset development, immune regulation, inflammatory response, and tumor metastasis. It can also mediate intercellular interactions and participate in tissue repair. ...
Highlights Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer. Carina’s CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed on colorectal cancer and other cancers. Colorectal ...
Highlights Five conference abstracts will be presented as poster presentations at AACR in the immuno-oncology and preclinical immunotherapy sessions Four presentations describe preclinical data from Carina’s LGR5-targeted CAR-T cell program, one poster will describe preclinical data from Carina’s ADAM-10 CAR-T program With its LGR5 CAR-T, Carina is progressing towards a ...
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with advanced colorectal (bowel) cancer ...
Whether it's to clarify new biomarkers for improved diagnostic methods and drug development, or to confirm existing markers in various types and stages of tumors, or to choose the best target point for preclinical research, tumor markers have a significant impact on the progress and practical application of tumor ...
Signal transduction pathway discovery, tumor marker research, and post-translational modification studies can all benefit from targeted proteomics quantitative technologies. ...
TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4). ...
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late 2022. Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s ...
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this ...
The use of proteomics can comprehensively, dynamically and quantitatively analyze the changes of protein types and quantities in normal and cancerous specimens, which not only can help to elucidate the pathogenesis of tumors but can also screen and identify tumor-specific markers and specific antigens. It can then be further applied to the early ...
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. (“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence ...
The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
Carina Biotech is delighted to announce it has raised AU$5.4 million. The raise was strongly supported by current shareholders, board and management and attracted new institutional and impact investors including a cornerstone investment from the Minderoo Foundation. The funding will enable us to undertake the required studies to initiate a clinical trial of our lead LGR5-targeted CAR-T program ...
Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer drug-carrier. ...
However, given the surgical site often lies in soft tissue, exact identification of the native tumor bed can present some difficulty for radiation planning. The surgical and radiation oncology team at Providence Mission Hospital (Mission Viejo, Ca) elected to use a novel tumor bed marker called VeraForm for a sarcomatoid carcinoma. ...
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed ...